| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| KLK14 | SPINK5 | ENSP00000375678 | ENSP00000352936 | Kallikrein-14; Serine-type endopeptidase with a dual trypsin-like and chymotrypsin-like substrate specificity. May activate/inactivate the proteinase-activated receptors F2R, F2RL1 and F2RL3 and other kallikreins including KLK1, KLK3, KLK5 and KLK11. May function in seminal clot liquefaction through direct cleavage of the semenogelin SEMG1 and SEMG2 and activation of KLK3. May function through desmoglein DSG1 cleavage in epidermal desquamation a process by which the most superficial corneocytes are shed from the skin surface. May be involved in several aspects of tumor progression incl [...] | Serine protease inhibitor Kazal-type 5; Serine protease inhibitor, probably important for the anti-inflammatory and/or antimicrobial protection of mucous epithelia. Contribute to the integrity and protective barrier function of the skin by regulating the activity of defense- activating and desquamation-involved proteases. Inhibits KLK5, it’s major target, in a pH-dependent manner. Inhibits KLK7, KLK14 CASP14, and trypsin; Serine peptidase inhibitors, Kazal type | 0.836 |
| KLK14 | SPINK9 | ENSP00000375678 | ENSP00000367139 | Kallikrein-14; Serine-type endopeptidase with a dual trypsin-like and chymotrypsin-like substrate specificity. May activate/inactivate the proteinase-activated receptors F2R, F2RL1 and F2RL3 and other kallikreins including KLK1, KLK3, KLK5 and KLK11. May function in seminal clot liquefaction through direct cleavage of the semenogelin SEMG1 and SEMG2 and activation of KLK3. May function through desmoglein DSG1 cleavage in epidermal desquamation a process by which the most superficial corneocytes are shed from the skin surface. May be involved in several aspects of tumor progression incl [...] | Serine protease inhibitor Kazal-type 9; Serine protease inhibitor which specifically inhibits KLK5. May contribute to the regulation of the desquamation process in skin by inhibiting KLK5; Serine peptidase inhibitors, Kazal type | 0.569 |
| KLK5 | KLK7 | ENSP00000337733 | ENSP00000375683 | Kallikrein-5; May be involved in desquamation; Belongs to the peptidase S1 family. Kallikrein subfamily | Kallikrein-7; May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at ’14-Tyr-|-Gln-15’ and insulin B chain at ’6- Leu-|-Cys-7’, ’16-Tyr-|-Leu-17’, ’25-Phe-|-Tyr-26’ and ’26-Tyr-|- Thr-27’. Could play a role in the activation of precursors to inflammatory cytokines; Kallikreins | 0.693 |
| KLK5 | KLK8 | ENSP00000337733 | ENSP00000375682 | Kallikrein-5; May be involved in desquamation; Belongs to the peptidase S1 family. Kallikrein subfamily | Kallikrein-8; Kallikrein related peptidase 8; Kallikreins | 0.957 |
| KLK5 | SPINK5 | ENSP00000337733 | ENSP00000352936 | Kallikrein-5; May be involved in desquamation; Belongs to the peptidase S1 family. Kallikrein subfamily | Serine protease inhibitor Kazal-type 5; Serine protease inhibitor, probably important for the anti-inflammatory and/or antimicrobial protection of mucous epithelia. Contribute to the integrity and protective barrier function of the skin by regulating the activity of defense- activating and desquamation-involved proteases. Inhibits KLK5, it’s major target, in a pH-dependent manner. Inhibits KLK7, KLK14 CASP14, and trypsin; Serine peptidase inhibitors, Kazal type | 0.972 |
| KLK5 | SPINK9 | ENSP00000337733 | ENSP00000367139 | Kallikrein-5; May be involved in desquamation; Belongs to the peptidase S1 family. Kallikrein subfamily | Serine protease inhibitor Kazal-type 9; Serine protease inhibitor which specifically inhibits KLK5. May contribute to the regulation of the desquamation process in skin by inhibiting KLK5; Serine peptidase inhibitors, Kazal type | 0.994 |
| KLK6 | SPINK5 | ENSP00000366047 | ENSP00000352936 | Kallikrein-6; Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neu [...] | Serine protease inhibitor Kazal-type 5; Serine protease inhibitor, probably important for the anti-inflammatory and/or antimicrobial protection of mucous epithelia. Contribute to the integrity and protective barrier function of the skin by regulating the activity of defense- activating and desquamation-involved proteases. Inhibits KLK5, it’s major target, in a pH-dependent manner. Inhibits KLK7, KLK14 CASP14, and trypsin; Serine peptidase inhibitors, Kazal type | 0.670 |
| KLK6 | SPINK9 | ENSP00000366047 | ENSP00000367139 | Kallikrein-6; Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neu [...] | Serine protease inhibitor Kazal-type 9; Serine protease inhibitor which specifically inhibits KLK5. May contribute to the regulation of the desquamation process in skin by inhibiting KLK5; Serine peptidase inhibitors, Kazal type | 0.542 |
| KLK7 | KLK5 | ENSP00000375683 | ENSP00000337733 | Kallikrein-7; May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at ’14-Tyr-|-Gln-15’ and insulin B chain at ’6- Leu-|-Cys-7’, ’16-Tyr-|-Leu-17’, ’25-Phe-|-Tyr-26’ and ’26-Tyr-|- Thr-27’. Could play a role in the activation of precursors to inflammatory cytokines; Kallikreins | Kallikrein-5; May be involved in desquamation; Belongs to the peptidase S1 family. Kallikrein subfamily | 0.693 |
| KLK7 | KLK8 | ENSP00000375683 | ENSP00000375682 | Kallikrein-7; May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at ’14-Tyr-|-Gln-15’ and insulin B chain at ’6- Leu-|-Cys-7’, ’16-Tyr-|-Leu-17’, ’25-Phe-|-Tyr-26’ and ’26-Tyr-|- Thr-27’. Could play a role in the activation of precursors to inflammatory cytokines; Kallikreins | Kallikrein-8; Kallikrein related peptidase 8; Kallikreins | 0.596 |
| KLK7 | SPINK5 | ENSP00000375683 | ENSP00000352936 | Kallikrein-7; May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at ’14-Tyr-|-Gln-15’ and insulin B chain at ’6- Leu-|-Cys-7’, ’16-Tyr-|-Leu-17’, ’25-Phe-|-Tyr-26’ and ’26-Tyr-|- Thr-27’. Could play a role in the activation of precursors to inflammatory cytokines; Kallikreins | Serine protease inhibitor Kazal-type 5; Serine protease inhibitor, probably important for the anti-inflammatory and/or antimicrobial protection of mucous epithelia. Contribute to the integrity and protective barrier function of the skin by regulating the activity of defense- activating and desquamation-involved proteases. Inhibits KLK5, it’s major target, in a pH-dependent manner. Inhibits KLK7, KLK14 CASP14, and trypsin; Serine peptidase inhibitors, Kazal type | 0.733 |
| KLK7 | SPINK9 | ENSP00000375683 | ENSP00000367139 | Kallikrein-7; May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at ’14-Tyr-|-Gln-15’ and insulin B chain at ’6- Leu-|-Cys-7’, ’16-Tyr-|-Leu-17’, ’25-Phe-|-Tyr-26’ and ’26-Tyr-|- Thr-27’. Could play a role in the activation of precursors to inflammatory cytokines; Kallikreins | Serine protease inhibitor Kazal-type 9; Serine protease inhibitor which specifically inhibits KLK5. May contribute to the regulation of the desquamation process in skin by inhibiting KLK5; Serine peptidase inhibitors, Kazal type | 0.556 |
| KLK8 | KLK5 | ENSP00000375682 | ENSP00000337733 | Kallikrein-8; Kallikrein related peptidase 8; Kallikreins | Kallikrein-5; May be involved in desquamation; Belongs to the peptidase S1 family. Kallikrein subfamily | 0.957 |
| KLK8 | KLK7 | ENSP00000375682 | ENSP00000375683 | Kallikrein-8; Kallikrein related peptidase 8; Kallikreins | Kallikrein-7; May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at ’14-Tyr-|-Gln-15’ and insulin B chain at ’6- Leu-|-Cys-7’, ’16-Tyr-|-Leu-17’, ’25-Phe-|-Tyr-26’ and ’26-Tyr-|- Thr-27’. Could play a role in the activation of precursors to inflammatory cytokines; Kallikreins | 0.596 |
| KLK8 | SPINK5 | ENSP00000375682 | ENSP00000352936 | Kallikrein-8; Kallikrein related peptidase 8; Kallikreins | Serine protease inhibitor Kazal-type 5; Serine protease inhibitor, probably important for the anti-inflammatory and/or antimicrobial protection of mucous epithelia. Contribute to the integrity and protective barrier function of the skin by regulating the activity of defense- activating and desquamation-involved proteases. Inhibits KLK5, it’s major target, in a pH-dependent manner. Inhibits KLK7, KLK14 CASP14, and trypsin; Serine peptidase inhibitors, Kazal type | 0.515 |
| KLK8 | SPINK9 | ENSP00000375682 | ENSP00000367139 | Kallikrein-8; Kallikrein related peptidase 8; Kallikreins | Serine protease inhibitor Kazal-type 9; Serine protease inhibitor which specifically inhibits KLK5. May contribute to the regulation of the desquamation process in skin by inhibiting KLK5; Serine peptidase inhibitors, Kazal type | 0.836 |
| LCE6A | SPINK9 | ENSP00000411070 | ENSP00000367139 | Late cornified envelope protein 6A; Precursors of the cornified envelope of the stratum corneum | Serine protease inhibitor Kazal-type 9; Serine protease inhibitor which specifically inhibits KLK5. May contribute to the regulation of the desquamation process in skin by inhibiting KLK5; Serine peptidase inhibitors, Kazal type | 0.538 |
| SPINK14 | SPINK2 | ENSP00000349459 | ENSP00000425961 | Serine protease inhibitor Kazal-type 14; May be a serine protease inhibitor; Serine peptidase inhibitors, Kazal type | Serine peptidase inhibitor, Kazal type 2 | 0.422 |
| SPINK14 | SPINK4 | ENSP00000349459 | ENSP00000369045 | Serine protease inhibitor Kazal-type 14; May be a serine protease inhibitor; Serine peptidase inhibitors, Kazal type | Serine peptidase inhibitor, Kazal type 4 | 0.416 |
| SPINK14 | SPINK9 | ENSP00000349459 | ENSP00000367139 | Serine protease inhibitor Kazal-type 14; May be a serine protease inhibitor; Serine peptidase inhibitors, Kazal type | Serine protease inhibitor Kazal-type 9; Serine protease inhibitor which specifically inhibits KLK5. May contribute to the regulation of the desquamation process in skin by inhibiting KLK5; Serine peptidase inhibitors, Kazal type | 0.510 |
